Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Nordsmark, M ^a   Maxwell, R J ^b   Wood, P J ^c   Stratford, I J ^d   Adams, G E ^c   Overgaard, J ^a   Horsman, M R ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Energy metabolism; Hypoxia; Tumour oxygenation; Vasoactive agent

Indexed keywords

HYDRALAZINE; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATE; OXYGEN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST TUMOR; CANCER TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENERGY METABOLISM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; OXYGEN ELECTRODE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TISSUE OXYGENATION; TUMOR BLOOD FLOW; TUMOR CELL; ANIMAL; ARTICLE; ELECTRODE; EXPERIMENTAL NEOPLASM; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; ELECTRODES; ENERGY METABOLISM; FEMALE; HYDRALAZINE; MAGNETIC RESONANCE SPECTROSCOPY; MAMMARY NEOPLASMS, ANIMAL; MICE; OXYGEN; VASODILATOR AGENTS;

EID: 0029922606     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. BHUJWALLA ZM, TOZER GM, FIELD SB, MAXWELL RJ AND GRIFFITHS JR. (1990). The energy metabolism of RIF-1 tumours following hydralazine. Radiother. Oncol., 19, 281-291.
2. BREMNER JCM, STRATFORD IJ, BOWLER J AND ADAMS GE. (1990). Bioreductive drugs and the selective induction of tumour hypoxia. Br. J. Cancer. 61, 717-721.
3. 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification. Br. J. Cancer, 64, 862-866.
4. CHAPLIN DJ AND ACKER B. (1987). The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int. J. Radiat. Oncol. Biol. Phys., 13, 579-585.
5. CHAPLIN DJ, ACKER B AND OLIVE PL. (1989). Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int. J. Radiat. Oncol. Biol. Phys., 16, 1131-1135.
6. DEWHIRST MW, MADWED D, MEYER RE, ONG ET, KLITZMAN B, ROSNER, GL AND DODGE R. (1994). Reduction in tumor blood flow in skin flap tumor after hydralazine is not due to a vascular steal phenomenon. Radiat. Oncol. Invest., 1, 270-278.
7. FIELD SB, BURNEY IA, NEEDHAM S, MAXWELL RJ, COGGLE JE AND GRIFFITHS JR. (1991). Are transplanted tumours suitable as models for studies on vasculature. Int. J. Radiat. Biol., 60, 255-260.
8. HORSMAN MR, CHRISTENSEN KL AND OVERGAARD J. (1989). Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int. J. Hyperther., 5, 123-136.
9. HORSMAN MR, KHALIL AA, NORDSMARK M, SIEMANN DW, HILL SA, LYNCH EM, CHAPLIN DJ, STERN S, THOMAS CD, GUICHARD M, GRAU C AND OVERGAARD J. (1995a). The use of oxygen electrodes to predict radiobiological hypoxia in tumours. In Tumour Oxygenation. Vaupel PW, Kelleher DK & Günderoth M. (eds) pp. 49-57. Gustav Fischer: Stuttgart, New York.
10. HORSMAN MR, NORDSMARK M, HØYER M AND OVERGAARD J. (1995b). Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous tumours. Br. J. Cancer, 72, 1474-1478.
11. 2-histography. Int. J. Radiat. Oncol. Biol. Phys., 19, 953-961.
12. KALMUS J, OKUNIEFF P AND VAUPEL P. (1990). Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors. Cancer Res., 50, 15-19.
13. LEMMON MJ AND BROWN JM. (1991). Hydralazine does not increase hypoxia in tumors growing in preirradiated tissue. Int. J. Radiat. Oncol. Biol. Phys., 21, 1435-1440.
14. LIN JC AND SONG CW. (1990). Effects of hydralazine on the blood flow in RIF-1 tumors and normal tissues of mice. Radiat. Res., 124, 171-177.
15. OKUNIEFF P, KALLINOWSKI F, VAUPEL P AND NEURINGER LJ. (1988). Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in rivo 31 P-nuclear magnetic resonance spectroscopy. J. Natl Cancer Inst., 80, 745-750.
16. ORDIDGE RG, CONNELLY A AND LOHMAN JAB. (1986). Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J. Magn. Reson., 66, 283-294.
17. SKARSGARD LD, CHAPLIN DJ, WILSON DJ, SKWARCHUK MW, VINCZAN A AND KRISTL J. (1992). The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int. J. Radiat. Oncol. Biol. Phys., 22, 737-741.
18. STRATFORD IJ, GODDEN J, HOWELLS N, EMBLING P AND ADAMS GE. (1987). Manipulation of tumor oxygenation by hydralazine increases the potency of bioreductive radiosensitizers and enhances the effect of melphalan in experimental tumors. In Proceedings of the Eighth International Congress on Radiation Research, Vol. 2, Fielden EM, Fowler JF, Hendry JH & Scott D. (eds) pp. 737-742. Taylor & Francis: London.
19. TOZER GM, MAXWELL RJ, GRIFFITHS JR AND PHAM P. (1990). Modification of the 31-P magnetic resonance spectra of a rat tumor using vasodilators and its relationship to hypotension. Br. J. Cancer, 62, 553-560.
20. 31P-NMR signals using the variable projection method and prior knowledge. Magn. Reson. Med., 6, 92-98.
21. VOORHEES WD AND BABBS CF. (1982). Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur. J. Cancer Clin. Oncol., 19, 1027-1033.
22. 31P magnetic resonance spectroscopy. Int. J. Radiat. Oncol. Biol. Phys., 22, 473-476.